Drugs / Dual Specificity CD38 and BCMA CAR-T Cells
Dual Specificity CD38 and BCMA CAR-T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03767751 | Dec 2018 → Dec 2022 | plasma cell myeloma | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dual Specificity CD38 and BCMA CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03767751 ↗ |
| Action | Deplete | “Dual Specificity CD38 and BCMA CAR-T cells can recognize and kill the malignant cells through recognition of CD38 or BCMA.” NCT03767751 ↗ |
| Modality | Cell therapy | “CAR-T cell therapy” NCT03767751 ↗ |
| Route | Intravenous | “The CAR-T cells will be administered by i.v. injection over 20-30 minutes” NCT03767751 ↗ |